PSF1 (partner of sld five 1) is an evolutionarily conserved DNA replication factor implicated in DNA replication in lower species that is strongly expressed in a wide range of normal stem cell populations and progenitor cell populations. Because stem and progenitor cells possess high proliferative capacity, we hypothesized that PSF1 may play an important role in tumor growth. To begin to investigate PSF1 function in cancer cells, we cloned the mouse PSF1 promoter and generated lung and colon carcinoma cells that stably express a PSF1 promoter-reporter gene. Reporter expression in cells correlated with endogenous PSF1 mRNA expression. In a tumor cell xenograft model, high levels of reporter expression correlated with high proliferative activity, serial transplantation potential, and metastatic capability. Notably, cancer cells expressing reporter levels localized to perivascular regions in tumors and displayed expression signatures related to embryonic stem cells. RNAi-mediated silencing of endogenous PSF1 inhibited cancer cell growth by disrupting DNA synthesis and chromosomal segregation. These findings implicate PSF1 in tumorigenesis and offer initial evidence of its potential as a theranostic target. Cancer Res; 70(3); 1215-24. ©2010 AACR.
Introduction
PSF1 (partner of SLD5) is a member of the tetrameric complex termed GINS, composed of SLD5, PSF1, PSF2, and PSF3, and is well conserved evolutionarily. In yeast, the GINS complex associates with the MCM2-7 complex and CDC45, and this "C-M-G complex" (CDC45-MCM2-7-GINS) regulates both the initiation and the progression of DNA replication (1) (2) (3) (4) (5) (6) . In Xenopus and human, GINS has been suggested to be involved in DNA replication because of its binding to DNA replication protein (7) (8) (9) (10) ; however, a recent study suggests that PSF1/2 is associated with the response to replication stress and acquisition of DNA damage in untransformed human dermal fibroblasts (11) . Thus, the exact functions of GINS components in mammalian cells are not yet clear.
We have previously cloned the mouse ortholog of PSF1 from a hematopoietic stem cell cDNA library (12) and found that PSF1 expression in mice was predominantly observed in the adult bone marrow and thymus, as well as the testis and ovary (i.e., tissues in which stem cell proliferation is actively induced and continues after birth). Moreover, we reported that PSF1 is strongly expressed in different immature cell lineages, such as cells in the inner cell mass during early embryogenesis as well as spermatogonia and hematopoietic stem cells after birth (12) (13) (14) . Loss of PSF1 led to embryonic lethality around the implantation stage caused by the inability of cells of the inner cell mass to proliferate (12) . Moreover, haploinsufficiency of PSF1 in PSF1 +/− mice resulted in the delayed induction of hematopoietic stem cell proliferation during reconstitution of bone marrow after 5-fluorouracil ablation. These data strongly suggest that PSF1 is required for acute proliferation of cells, especially immature cells such as stem cells and progenitor cells.
Several recent studies have suggested that GINS components play a role not only in immature cells from normal tissues, as we reported, but also in cancer cells. For example, all GINS components were found to be overexpressed in intrahepatic cholangiocarcinoma tissues (15) . A Gene Expression Omnibus (GEO) database search revealed that PSF1 is an estrogen target in MCF7 human breast carcinoma cells (16) . In a comprehensive study, it was found that PSF1 and SLD5 were upregulated in aggressive melanoma (17) . Based on these results, we examined the nature of cells highly expressing PSF1 in a tumor xenograft model.
Genetic events caused by epigenetic modulation and microenvironmental exposure have been suggested to be responsible for tumor progression. Therefore, a species-matched (murine) microenvironment is needed to examine the nature of cells strongly expressing PSF1.
Here, we have investigated the expression of PSF1 and the localization of PSF1-positive cancer cells in a mouse tumor cell xenograft model. We observed malignant behavior of highly PSF1-positive tumor cells with regard to tumorigenesis and metastasis. Moreover, highly PSF1-positive cancer cells have been characterized by microarray analysis, and the data compared with those of the recently reported embryonic stem cell (ESC)-like gene expression signature in poorly differentiated aggressive human tumors (18) . Finally, to determine whether PSF1 could be a molecular target for the development of anticancer drugs, we silenced the PSF1 gene by the RNA interference (RNAi) method in human carcinoma cell lines and observed the effects thereof on the growth of the cancer cells.
Materials and Methods
Cell culture and cell line construction. LLC, B16, NIH3T3, HeLa, and HEK293T were maintained in DMEM (Sigma) with 10% fetal bovine serum (FBS; Sigma) and penicillin/streptomycin (Life Technologies, Inc.). Colon26 cells were maintained in RPMI 1640 (Sigma) with 10% FBS and penicillin/ streptomycin. Mouse embryonic fibroblasts were prepared from day 14.5 embryos and cultured in high-glucose DMEM (Sigma) with 10% FBS and penicillin/streptomycin.
The gene encoding the PSF1 promoter region was isolated by mouse BAC cloning (RP23-193L22, Advanced GenoTechs Co.). Using the 5′ upstream sequence of the first exon of the PSF1 locus as a probe, 5.5 kb of the 5′flanking PSF1 gene were isolated and subcloned into pBluescript II KS (Stratagene). The enhanced green fluorescent protein (EGFP) gene and the neomycin gene were excised from pEGFP-N1 and pcDNA3.1(−) (Clontech), respectively, and ligated to the 5.5 kb of the PSF1 5′-flanking fragment. This construct was designated PSF1p-EGFP. LLC and colon26 cells were transfected using Lipofectamine 2000 (Invitrogen). After transfection, the cells were cultured in medium supplemented with G418 (Life Technologies) to obtain cells stably expressing EGFP under the control of the PSF1 promoter (LLC-PSF1p-EGFP and colon26-PSF1p-EGFP).
Quantitative reverse transcription-PCR. Quantitative reverse transcription-PCR (RT-PCR) was done as previously described (14) . The primer sets were described in Supplementary Materials and Methods.
Mice. Seven-to eight-week-old C57BL/6 female mice (for the LLC experiments) and BALB/c female mice of the same age (for colon26) were purchased from Japan SLC. All animal studies were approved by the Osaka University Animal Care and Use Committee. Subcutaneous xenografts were established by injecting 10 6 cells into the flanks of the mice. Flow cytometric analysis. Single-cell suspensions from tumors were prepared using a standard protocol. Cell sorting was done using a FACSAria (Becton Dickinson). For the EGF-P high population, the 5% most brightly fluorescing cells were sorted, and for the EGFP low population, the 5% least fluorescent. We used parental LLC or colon26 as negative controls.
In vitro clonal analyses and in vivo tumorigenicity analysis. Isolated cells were plated on 10-cm culture dishes (200 per dish for LLC-PSF1p-EGFP and 100 per dish for colon26-PSF1p-EGFP) and cultured. The percentage of cells that initiated a clone was taken as the plating efficiency. For in vivo experiments, 100 sorted cells in 100 μL of PBS with growth factor-reduced Matrigel (BD Biosciences; 1:1) were injected s.c. into the mice. Five weeks after injection, tumor volumes were measured with a caliper and calculated as width × width × length × 0.52.
Invasion assay and metastasis assay. The invasive activity of tumor cells was assayed using a BioCoat Matrigel Invasion Chamber (BD Biosciences) according to the manufacturer's instruction.
For the lung metastasis assay using LLC-PSF1p-EGFP, 10 5 viable sorted cells were injected into the tail veins of mice. After 4 wk, lungs were dissected and the number of colonies observable on the surface of the lungs was noted. For the hepatic metastasis assay of colon26-PSF1p-EGFP, spleens of mice were exposed to allow the direct injection of 5 × 10 4 viable sorted cells. After 12 d, livers and spleens were dissected out and the number of colonies observable on the surface of the livers was recorded. Sections of liver were stained with H&E to evaluate tissue morphology and to detect metastases.
Immunohistochemistry and immunocytochemistry. Immunohistochemical analyses were done as previously described (19) . Rabbit anti-GFP antibody (Invitrogen) and rat anti-CD31 (BD Biosciences) were used for primary antibodies. For the fluorescent immunohistochemical analyses, phycoerythrin-conjugated anti-CD31 (BD Biosciences) was used for staining endothelial cells.
For immunocytochemistry, anti-PSF1(14), anti-bromodeoxyuridine (BrdUrd) (Zymed Laboratories), anti-β-tubulin (Sigma), anti-CENP-A (MBL), and anti-survivin (Chemicon International, Inc.) antibodies were used as previously described (14) .
PSF1 knockdown. Transfection was done using Lipofectamine 2000 (Invitrogen). For the enrichment of transiently shRNA vector-transfected cells, the puromycin resistance gene was ligated into the XhoI site of the pSINsi-hU6 vector (Takara), and then sense and antisense oligonucleotide pairs (see below) were annealed and ligated into the BamHI/ClaI site of the pSINsi-hU6-P vectors. The sequences of the oligonucleotide sets were described in Supplementary Materials and Methods. For time-lapse imaging of histone H3 and tubulin in living cells, HEK293T cells were transfected with GFP-histone (20) or tubulin-GFP (Clontech) expression vectors, and stably expressing clones were selected. Time-lapse observation was done as previously reported using an IX70 microscope (Olympus; ref. 21) .
Microarray and bioinformatics analysis. Microarrays were done as previously described (22) . Raw data are available for download from GEO (GSE17112). Gene set enrichment analysis (GSEA; ref. 23 ) was done by CeresBioscience as previously reported.
Statistical analysis. Results were expressed as the mean ± SEM. Student's t test was used for statistical analysis. Differences were considered statistically significant when P < 0.01.
Results
Establishment of transgenic cell lines to monitor endogenous PSF1 expression in living cells. We first examined PSF1 mRNA expression in mouse cancer cell lines, a noncancer cell line, and primary cultured cells. PSF1 mRNA in cancer cell lines is expressed to a greater degree than in the noncancer cell line or primary cultured cells (Fig. 1A) . To determine whether the cancer cells strongly expressing PSF1 had malignant features, they need to be collected as living cells. Because PSF1 is an intracellular protein, viable cells cannot be isolated using PSF1 antibody and flow cytometric cell sorting. Therefore, we used promoter activity to monitor the expression level of PSF1 in cancer cells in the murine tumor xenograft model. We have cloned the mouse PSF1 promoter gene and established lung carcinoma [Lewis lung carcinoma (LLC)] and colon cancer (colon26) cell lines stably expressing EGFP under the transcriptional control of the PSF1 promoter (LLC-and colon26-PSF1p-EGFP, respectively). We confirmed PSF1 mRNA expression in parental LLC and colon26 cells (data not shown). After inoculation of LLCPSF1p-EGFP, tumors were dissected and the intensity of EGFP in dissociated cancer cells was analyzed by flow cytometry ( Fig. 1B-D) . As can be seen, EGFP-positive (EGFP + ) cells containing high or low levels of EGFP (EGFP high or EGF-P low cells, respectively) were present. These were separated and the expression of PSF1 mRNA was examined (Fig. 1D) . The results indicate that the intensity of EGFP is correlated with the endogenous PSF1 expression. Similar results were obtained using colon26-PSF1p-EGFP (data not shown). These results suggest that these cell lines are useful tools to monitor endogenous PSF1 expression in living cells.
EGFP(PSF1) high cells possess greater tumorigenic capacity. To study their colony forming efficiency, cancer cells (LLC-and colon26-PSF1p-EGFP) from tumor-bearing mice were divided into three fractions (EGFP + , EGFP low , and EGFP high ) as indicated in Fig. 1C (Fig. 2B) . When tumor cell components were examined in tumors generated after the second transplantation, EGFP high cells were found to have given rise to both EGFP high and EGFP low cells in both LLC and colon26 tumors (Supplementary Fig. S1 ). Taken together, these data suggest that cancer cells expressing higher levels of PSF1 exhibit high cloning efficiency and tumorigenicity.
EGFP(PSF1) high cells possess greater invasive and metastatic capacity. We investigated that EGFP high cells also play a crucial role in tumor metastasis. We determined the overall ability of cells sorted, as described in Fig. 1C, for invasion (Fig. 3A and B) .
Next, we examined the in vivo metastatic potential of these cells by two different means. First, viable sorted EGFP high or EGFP low cells from LLC tumors were injected into the tail veins of recipient mice. After 4 weeks, macrometastatic lesions in the lung were enumerated. Results clearly indicated that EGFP high cells had a higher metastatic potential than did EGF-P low cells ( Fig. 3C; Supplementary Fig. S2A ). Second, in the case of colon26 tumors, viable sorted EGFP high or EGFP low cells were injected into the spleen. After 12 days, metastatic nodules in the liver were analyzed on liver sections. EGFP low cells rarely generated metastatic foci, but large lesions were frequently observed in the livers of mice injected with EGFP high cells ( Fig. 3C; Supplementary Fig. S2B ).
ESC-like signatures are enriched in EGFP high cells versus EGFPlow cells. Recent studies showed that poor prognosis in a diverse set of human and mouse malignancies is associated with the expression of an ESC-like genetic program (18 (Fig. 4) . Interestingly, other ESC-like signatures (24, 25) , in which some cancer-initiating/stem cells (CIC/CSC) were enriched, were also enriched in EGFP high cells versus EGFP low cells ( Fig. 4 ; Supplementary Table S1 ). Taken together, the results from all the above experiments lead us to conclude that cancer cells harboring large amounts of PSF1 or high transcriptional activity of PSF1 possess malignant features, including high proliferative capacity, tumorigenesis, metastatic ability, and genetic profiles of poor prognosis. PSF1 high cells are localized in perivascular regions. Next, the tissue distribution of EGFP high cells in tumors was examined ( Fig. 5A-C) . EGFP high cells were located close to the edge of the tumor and near the blood vessels. Preliminary, we investigated PSF1 expression in human carcinoma specimens ( Supplementary Fig. S3 ). We found that PSF1 expression in human lung and esophageal squamous cell carcinoma specimens was confined to the surrounding basal-like cells and located at some distance from the centers of terminal differentiation zones. Furthermore, PSF1-positive cells were located in close proximity to blood vessels near the edge of the tumor, as observed in our murine xenograft model (Supplementary Fig. S3) .
Silencing of PSF1 inhibits the proliferation of carcinoma cells. Targeted disruption of PSF1 led to embryonic lethality caused by the inhibition of cell growth in the inner cell mass (12) , suggesting that silencing this gene may also inhibit tumor cell proliferation. To determine whether PSF1 could be a suitable molecular target for anticancer drug development, the inhibitory effects of its expression in human carcinoma cell lines should be evaluated. In budding yeast, it has been suggested that PSF1 plays a role in DNA replication, associated with the formation of the DNA replication fork (7) (8) (9) . However, its function in mammalian cells has not been clarified. First, we established the cellular localization of PSF1 in HeLa cells (Fig. 6A) . At interphase, PSF1 was localized predominantly in the nuclei. During mitosis, it was almost exclusively diffusely located outside the chromatin. Next, we used short hairpin RNA (shRNA) expression plasmids for RNAimediated endogenous gene silencing in HeLa cells in vitro. Quantitative RT-PCR with gene-specific shRNA confirmed that endogenous PSF1 gene expression was reduced by more than 75% within 72 hours, compared with the lack of effect of transfection of a scrambled shRNA expression plasmid (data not shown). At 96 hours, the total number of PSF1 shRNAtreated cells was significantly decreased compared with the control (Fig. 6B) , suggesting that depletion of PSF1 had resulted in cell growth arrest. To analyze more precisely the effect of PSF1 depletion on cell growth, first, the DNA contents were analyzed (Fig. 6C, left) . Results showed that depletion of PSF1 led to an increase in the fraction of cells in the sub-G 1 , S, and G 2 -M phases, suggesting that this molecule is important not only for S phase but also for G 2 -M phase progression.
Polyploid cells can arise as a result of errors in mitosis. These cells usually exit the cycle in an aberrant fashion, without sister chromatid segregation or cytokinesis, a process known as "mitotic slippage." Cancer cell lines (such as HeLa and HEK293T cells) lacking functional p53 progress into S phase without p53-dependent growth arrest at the subsequent G 1 -S boundary, and hyperploid cells develop as a result. However, no obvious hyperploid cell populations were found in PSF1-depleted cells (Fig. 6C, left) . During a 4-hour pulse, approximately 75% of scrambled shRNA-treated cells incorporated BrdUrd (Fig. 6C, right) , but only approximately 23% of PSF1-depleted cells possessed large nuclei staining with anti-BrdUrd antibody. Taken together, these data indicate that PSF1 depletion also inhibits DNA synthesis of multiploid cells, which resulted in the generation of only a small number of cells harboring large nuclei (8N; Fig. 6C, left) .
During the 72-to 120-hour period after shRNA treatment, the population of G 2 -M phase cells increased in the PSF1 depletion experiments (Fig. 6C, left) . Therefore, we assessed the function of PSF1 in G 2 -M progression. In the scrambled shRNA-treated control population, most cells had divided within 60 minutes, whereas division times were prolonged in the PSF1-depleted cells (Fig. 6D, left) . To examine this in terms of chromosome segregation, real-time imaging was done with histone H2B-GFP, which labels the chromosomes (Fig. 6D, middle) . In control cells, the chromosomes were condensed and congressed to the metaphase plate, but subsequently, and suddenly, they completely segregated and the time spent in metaphase was between 15 and 30 minutes. By contrast, PSF1 depletion prolonged the duration of metaphase by between 33 and 145 minutes, and a proportion of the PSF1-depleted cells showed abnormal chromosome congression and segregation (data not shown). Real-time observation with GFP-tubulin also revealed that depletion of PSF1 caused arrest at metaphase (data not shown). To resolve whether this mitotic arrest, induced by PSF1 depletion, was dependent on the spindle assembly checkpoint, Mad2 was co-depleted from the cells. We found that the mitotic arrest of almost all co-depleted cells was rescued by the early onset of anaphase (Fig. 6D, right) . Taken together, these data showed that, in the absence of PSF1, the spindle checkpoint signal was activated and mitotic arrest was precipitated.
Because we observed abnormalities in metaphase arrest and DNA segregation in PSF1-depleted cells, we next analyzed spindle organization by staining for β-tubulin. Results showed that approximately 10% of the mitotic cells formed multipolar asters (Fig. 6E, left) , whereas a small number of abnormal spindles were found in the control experiments (data not shown). Moreover, by immunostaining with antisurvivin antibody, we found that unaligned chromosomes were present in PSF1 shRNA-treated cells, which may reflect a defect in chromosome congression or segregation (Fig. 6E,  middle) . Recently, we reported that PSF1-deficient mice were nonviable at around embryonic day E6.5 and that BrdUrd incorporation was inhibited in the cultured inner cell mass from the blastocysts of E3.5 PSF1 −/− embryos (12) . Consistent with the present results from RNAi experiments in HeLa cells, we found that micronuclei and abnormal chromosomal segregation occurred in E3.5 PSF1 −/− blastocysts (Fig. 6E,   right ). These data indicate that PSF1 contributes not only to DNA replication but also to the transition from metaphase to anaphase, as well as to chromosome segregation.
Discussion
In the present work, we used cells with a high level of expression of PSF1 to show that these malignant cancer cells, which are located in the vascular region and at the edge of the tumor, exhibit high tumorigenic and metastatic ability.
Thus far, acquisition of genetic changes affected by epigenetic manipulation and microenvironmental exposure has been suggested to be responsible for tumor progression. When we cultured the tumor cells in vitro, we observed that the population consisted of PSF1(EGFP) high and PSF1(EGFP) low fractions. When sorted and separately injected into mice, we failed to detect any marked differences between them in terms of tumorigenic or metastatic capacity (data not shown). When nonfractionated tumor cells from these cultures were injected, the tumors that developed consisted of both PSF1(EGFP) high and PSF1(EGFP) low cells. However, when these cells extracted from tumors in vivo were fractionated into PSF1(EGFP) high and PSF1(EGFP) low and injected into mice again, then we did see clear a difference in terms of tumorigenic and metastatic capacity between the two fractions.
Our model therefore strongly supports the possibility that environmental changes in vivo clearly affect the features of cancer cells with regard to tumorigenicity or nontumorigenicity. Thus, this model suggested that the interaction of cancer Figure 6 . PSF1 silencing inhibits proliferation of cancer cells. A, HeLa cells were immunostained with anti-PSF1 (green). DNA was counterstained with 4′,6-diamidino-2-phenylindole (DAPI; blue). B, total numbers of RNAi-treated HeLa cells 96 h after transfection (bottom). SCR, nonspecific scrambled shRNA as a negative control. *, P < 0.05. C, DNA content of shRNA-treated HeLa cells (72 h after transfection) was determined by flow cytometry (left). DNA synthesis in large nucleated cells treated with the indicated shRNA. Immunostaining was done with anti-BrdUrd antibody (red), and counterstaining with DAPI (blue; right). Arrows, large nuclei. D, HeLa cells were treated with control (blue) or PSF1 (red) shRNA. Time required for cell division was evaluated by time-lapse observation 72 to 96 h after transfection (left). Using histone H3-GFP-expressing HEK293T cells, metaphase retention time was observed 72 to 120 h after transfection (middle). The H3-GFP-HEK293T cells were cotransfected with PSF1 shRNA and scrambled shRNA (red) or PSF1 and Mad2 shRNA vectors (green), and metaphase retention time was observed 36 to 72 h after transfection (right). E, HeLa cells transfected with shRNA as indicated. Expression of tubulin (green) and CENP-A (red; left). DNA was counterstained with DAPI (blue). Expression of survivin (green; middle). DNA was counterstained with propidium iodide (red). E3.5 PSF1 +/+ or PSF1 −/− embryos were fixed and stained with propidium cells with their microenvironment changes them into more malignant ones. In our tumor model as well as histology of human tissues, cells highly positive for PSF1 are located near blood vessels. It has been suggested that CSCs/CICs localize in the perivascular region (26) , as is observed in normal organs, where stem cells are located in the vascular niche (27) . Furthermore, microarray data clearly indicated that ESC-like signatures, which are reported to be enriched in CSCs/CICs fractions, were also enriched in EGFP high cells versus EGFP low cells (Fig. 4) . Thus, the subpopulation of cells strongly positive for PSF1 might include the CSC/CIC fraction. Antitumor angiogenesis is a promising approach for managing cancer patients, and many angiogenesis-disrupting agents have been developed (28) . Although some agents have already been tested clinically and prolongation of survival has been confirmed, it is impossible to destroy all of the blood vessels in a tumor. Recent research in mice has suggested that the tumor repopulates from the edge region to the center after treatment with an angiogenesis-disrupting agent (28) , and also that malignant tumor cells egress through remnant blood vessels at the tumor edge after inhibition of vascular endothelial growth factor signals (29) . We previously reported that blood vessels in peripheral regions of tumors are well matured compared with those in the center and that they are resistant to antiangiogenic drugs (19, 30) . Our data therefore strongly support the notion that cells with malignant features located near blood vessels at the tumor edge and showing resistance to angiogenesis-disrupting agents are responsible for invasion and metastasis. Our present model represents a precise analytic tool to determine whether candidate drugs directed against cells with malignant features including CSCs/CICs or blood vessels actually do suppress proliferation of cancer cells or destroy the vascular niche.
Our data clearly indicate that PSF1 plays a pivotal role in DNA replication and microtubule organization. Recently, it has been suggested that molecules homologous with those associated with DNA replication in lower species also regulate other cellular events in mammalian cells (31) (32) (33) . In higher eukaryotes, a number of environmental cues affecting cell division involve DNA replication proteins that are also used by lower eukaryotes and that perform diverse functions in cytokinesis. Therefore, there is a possibility that, in addition to its role in microtubule organization, which we have shown here, plus the known part it plays in DNA replication, PSF1 may also have other cellular functions in symmetrical or asymmetrical cell division of malignant cancer cells by influencing cell structure. As we showed here, the possibility that PSF1 is expressed by malignant cancer cells, which may include CSCs or CICs, and the finding that silencing PSF1 induced cancer cell apoptosis suggest that this molecule may represent an important new target for the development of anticancer drugs.
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